Chimeric receptors and uses thereof in immune therapy
US-2015139943-A1 · May 21, 2015 · US
Chimeric antigen receptors targeted to PSCA
US11466097B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11466097-B2 |
| Application number | US-201615766674-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 6, 2016 |
| Priority date | Oct 6, 2015 |
| Publication date | Oct 11, 2022 |
| Grant date | Oct 11, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Chimeric transmembrane immunoreceptors (CAR) targeted to PSCA are described.
First claim
Opening claim text (preview).
What is claimed is: 1. A nucleic acid molecule encoding a chimeric antigen receptor comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 26, 28, 30, 32, 34 and 36. 2. A population of human T cells comprising a nucleic acid encoding a chimeric antigen receptor comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 26, 28, 30, 32, 34 and 36. 3. The population of human T cells of claim 2 , wherein the population of T cells comprises central memory T cells. 4. A chimeric antigen receptor comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 26, 28, 30, 32, 34 and 36. 5. The nucleic acid molecule of claim 1 , wherein the chimeric antigen receptor comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 26 and 32. 6. The nucleic acid molecule of claim 1 , wherein the chimeric antigen receptor comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 28 and 34. 7. The nucleic acid molecule of claim 1 , wherein the chimeric antigen receptor comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 30 and 36. 8. The population of human T cells of claim 2 , wherein the chimeric antigen receptor comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 26 and 32. 9. The population of human T cells of claim 2 , wherein the chimeric antigen receptor comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 28 and 34. 10. The population of human T cells of claim 2 , wherein the chimeric antigen receptor comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 30 and 36. 11. The chimeric antigen receptor of claim 4 , wherein the chimeric antigen receptor comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 26 and 32. 12. The chimeric antigen receptor of claim 4 , wherein the chimeric antigen receptor comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 28 and 34. 13. The chimeric antigen receptor of claim 4 , wherein the chimeric antigen receptor comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 30 and 36.
Assignees
Inventors
Classifications
viral genome or elements thereof as genetic vector · CPC title
Genetically modified cells · CPC title
Viral vectors · CPC title
fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies · CPC title
containing a transmembrane segment · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11466097B2 cover?
- Chimeric transmembrane immunoreceptors (CAR) targeted to PSCA are described.
- Who is the assignee on this patent?
- Hope City
- What technology area does this patent fall under?
- Primary CPC classification C07K16/3069. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).